PE20221271A1 - Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas - Google Patents
Moleculas de fusion del ecd de siglec-9 y metodos de uso de estasInfo
- Publication number
- PE20221271A1 PE20221271A1 PE2022000710A PE2022000710A PE20221271A1 PE 20221271 A1 PE20221271 A1 PE 20221271A1 PE 2022000710 A PE2022000710 A PE 2022000710A PE 2022000710 A PE2022000710 A PE 2022000710A PE 20221271 A1 PE20221271 A1 PE 20221271A1
- Authority
- PE
- Peru
- Prior art keywords
- siglec
- domain
- methods
- fusion molecules
- ecd fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Recrystallisation Techniques (AREA)
- External Artificial Organs (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO QUE COMPRENDE UN DOMINIO EXTRACELULAR (ECD) SIGLEC-9 QUE COMPRENDE EL DOMINIO SIGLEC-9 IGV QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LAS SEQ ID NO: 109-137 Y 214-226, UN DOMINIO C2 TIPO 1 (C2T1) Y UN DOMINIO C2 TIPO 2 (C2T2); DONDE EL POLIPEPTIDO COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LAS SEQ ID NO: 79-107 Y 194-206. DICHO POLIPEPTIDO BLOQUEA LA UNION CELULAR DE UNO O MAS MIEMBROS DE LA FAMILIA SIGLEC SELECCIONADOS DE SIGLEC-3, SIGLEC-5, SIGLEC-7, SIGLEC-9, SIGLEC-10 Y SIGLEC-15. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930227P | 2019-11-04 | 2019-11-04 | |
| US202063014940P | 2020-04-24 | 2020-04-24 | |
| US202063092753P | 2020-10-16 | 2020-10-16 | |
| PCT/US2020/058687 WO2021091885A2 (en) | 2019-11-04 | 2020-11-03 | Siglec-9 ecd fusion molecules and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221271A1 true PE20221271A1 (es) | 2022-09-01 |
Family
ID=73598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000710A PE20221271A1 (es) | 2019-11-04 | 2020-11-03 | Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11987612B2 (es) |
| EP (1) | EP4055031A2 (es) |
| JP (1) | JP2022553571A (es) |
| KR (1) | KR20220092918A (es) |
| CN (1) | CN114667298A (es) |
| AU (1) | AU2020378251A1 (es) |
| BR (1) | BR112022008321A2 (es) |
| CA (1) | CA3155345A1 (es) |
| CL (1) | CL2022001130A1 (es) |
| CO (1) | CO2022005587A2 (es) |
| CR (1) | CR20220244A (es) |
| EC (1) | ECSP22044316A (es) |
| IL (1) | IL292499A (es) |
| MX (1) | MX2022005376A (es) |
| PE (1) | PE20221271A1 (es) |
| TW (1) | TW202132329A (es) |
| WO (1) | WO2021091885A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021261524A1 (en) | 2020-04-24 | 2022-11-24 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| WO2024102635A1 (en) | 2022-11-07 | 2024-05-16 | Alector Llc | Uses of siglec-9 ecd fusion molecules in cancer treatment |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| EP1556684A4 (en) | 2002-11-01 | 2008-01-23 | Univ Colorado Regents | QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| GB0521991D0 (en) | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
| US20070244038A1 (en) | 2006-04-12 | 2007-10-18 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US9688756B2 (en) | 2011-12-21 | 2017-06-27 | Amgen Inc. | Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor |
| JP6403062B2 (ja) | 2012-12-21 | 2018-10-10 | 国立大学法人徳島大学 | 組織修復活性組成物及びその利用 |
| WO2014120642A1 (en) | 2013-01-30 | 2014-08-07 | The General Hospital Corporation | Diagnosis and treatment of hepatorenal syndrome |
| AU2015314316B2 (en) | 2014-09-10 | 2020-12-10 | Innate Pharma | Cross reactive Siglec antibodies |
| AU2016257721B2 (en) | 2015-05-01 | 2019-11-14 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
| EP3368575A2 (en) | 2015-10-29 | 2018-09-05 | Alector LLC | Anti-siglec-9 antibodies and methods of use thereof |
| EP3368894B1 (en) | 2015-10-30 | 2021-01-20 | Hach Company | Storage stable standards for aqueous chlorine analysis |
| US11083785B2 (en) * | 2015-11-17 | 2021-08-10 | Innate Pharma | Siglec-10 antibodies |
| EP3402516A4 (en) | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
| CN108699158B (zh) | 2016-03-08 | 2022-06-03 | 依奈特制药公司 | Siglec中和抗体 |
| GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| JP2019527204A (ja) | 2016-07-01 | 2019-09-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抑制性免疫受容体阻害方法および組成物 |
| JP2020527144A (ja) | 2017-07-10 | 2020-09-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
| US11623954B2 (en) | 2017-07-10 | 2023-04-11 | Innate Pharma | Siglec-9-neutralizing antibodies |
| CN112601757A (zh) | 2018-06-07 | 2021-04-02 | 帕利昂制药有限公司 | 用于检测糖类和/或治疗siglec介导的障碍的多聚体蛋白 |
| CN113164589A (zh) | 2018-06-29 | 2021-07-23 | 维西欧制药公司 | 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 |
| WO2020072593A1 (en) | 2018-10-02 | 2020-04-09 | Obi Pharma, Inc. | Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agents |
| US20220211831A1 (en) | 2019-04-17 | 2022-07-07 | Bar-Ilan University | Siglec-based chimeric polypeptides and uses thereof |
| WO2020247372A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| US20220283165A1 (en) | 2019-07-12 | 2022-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Enhancing Immunogenicity of Cancers |
-
2020
- 2020-11-03 TW TW109138156A patent/TW202132329A/zh unknown
- 2020-11-03 KR KR1020227017802A patent/KR20220092918A/ko unknown
- 2020-11-03 AU AU2020378251A patent/AU2020378251A1/en active Pending
- 2020-11-03 CR CR20220244A patent/CR20220244A/es unknown
- 2020-11-03 EP EP20816024.2A patent/EP4055031A2/en active Pending
- 2020-11-03 JP JP2022524955A patent/JP2022553571A/ja active Pending
- 2020-11-03 PE PE2022000710A patent/PE20221271A1/es unknown
- 2020-11-03 CA CA3155345A patent/CA3155345A1/en active Pending
- 2020-11-03 US US17/088,149 patent/US11987612B2/en active Active
- 2020-11-03 BR BR112022008321A patent/BR112022008321A2/pt unknown
- 2020-11-03 WO PCT/US2020/058687 patent/WO2021091885A2/en active Application Filing
- 2020-11-03 MX MX2022005376A patent/MX2022005376A/es unknown
- 2020-11-03 CN CN202080076354.8A patent/CN114667298A/zh active Pending
-
2022
- 2022-04-25 IL IL292499A patent/IL292499A/en unknown
- 2022-04-29 CO CONC2022/0005587A patent/CO2022005587A2/es unknown
- 2022-05-02 CL CL2022001130A patent/CL2022001130A1/es unknown
- 2022-06-02 EC ECSENADI202244316A patent/ECSP22044316A/es unknown
-
2024
- 2024-04-17 US US18/637,627 patent/US20240279305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022553571A (ja) | 2022-12-23 |
| CN114667298A (zh) | 2022-06-24 |
| WO2021091885A3 (en) | 2021-06-17 |
| US11987612B2 (en) | 2024-05-21 |
| CL2022001130A1 (es) | 2023-02-24 |
| EP4055031A2 (en) | 2022-09-14 |
| CR20220244A (es) | 2022-06-28 |
| US20240279305A1 (en) | 2024-08-22 |
| KR20220092918A (ko) | 2022-07-04 |
| CA3155345A1 (en) | 2021-05-14 |
| US20210284710A1 (en) | 2021-09-16 |
| IL292499A (en) | 2022-06-01 |
| ECSP22044316A (es) | 2022-07-29 |
| MX2022005376A (es) | 2022-05-19 |
| AU2020378251A1 (en) | 2022-05-26 |
| TW202132329A (zh) | 2021-09-01 |
| WO2021091885A2 (en) | 2021-05-14 |
| BR112022008321A2 (pt) | 2022-07-26 |
| CO2022005587A2 (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| CL2022001271A1 (es) | Agonista del receptor glp-1 y uso de este | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| PE20190335A1 (es) | Receptores de celulas t | |
| AR100888A1 (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| CL2017002345A1 (es) | Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR113455A1 (es) | Proteínas inmunomoduladoras de variantes del ligando de icos y composiciones y métodos relacionados | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| PE20170503A1 (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
| PE20130738A1 (es) | Dominios variables simples de inmunoglobulina anti-vegf | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| PE20221271A1 (es) | Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas | |
| PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| CL2023000752A1 (es) | Composiciones y métodos para tratar la enfermedad celiaca | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| AR113134A1 (es) | Arni variante | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas |